A cell therapy company working on autoimmune diseases isn’t outside the norm, given the industry trend this past year to leverage the modality for inflammatory and immunology (I&I) indications, but RegCell has a bit of an edge — the Japanese-founded biotech’s scientific founder Shimon Sakaguchi helped discover regulatory T cells (Tregs) and their role in maintaining immunological self-tolerance.
